Present Accomplishments and Future Prospects of Cell-Based Therapies for Type 1 Diabetes Mellitus

Chhabra, Preeti; Kensinger, Clark D.; Moore, Daniel J.; Brayman, Kenneth L.

doi:10.5772/22343

Cited by 7 publications

(8 citation statements)

References 217 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the intimate arrangement of heterogeneous cells in islets has been implicated in the functional regulation of islets [39]. The mechanisms responsible for changes in the number and ratio of endocrine cells are still unclear [4][5][6]. Therefore, it seems logical to examine these issues during prenatal human development.…”

Section: Pancreas Structure In Adultsmentioning

confidence: 99%

“…For example, it increases in cases of altered metabolic demand such as pregnancy and obesity, as well as during normal physiological growth [2,3]. According to the literature, mechanisms of pancreatic β-cell plasticity are associated with the processes of cell proliferation, cell death, neogenesis, and changes in cell volume [4][5][6]. Recent work in rodents has indicated a previously unappreciated proliferative capacity of β-cells.…”

Section: Introductionmentioning

confidence: 99%

“…It has been suggested that, in addition to the proliferation of existing β-cells, new cells can be obtained from differentiated adult pancreatic cells by interconverting between endocrine and exocrine parts. There are also suggestions regarding ontogenesis from duct cells or from other progenitor cells [6,15]. Acinar cells are another potential source of new pancreatic endocrine cells.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Ontogeny of the Human Pancreas

Proshchina¹,

Krivova²,

Гуревич³

et al. 2019

Comparative Endocrinology of Animals

View full text Add to dashboard Cite

Pancreatic disorders are the most common pathologies in humans worldwide. Detailed information on pancreatic cytoarchitecture, vascularisation, innervation, morphogenesis, and cell differentiation is required for the development of new approaches to the treatment of these diseases. Currently, the majority of studies on pancreas development are performed on experimental animals (mainly rodents). Studies on human pancreatic prenatal development are restricted in number by ethical constraints and some technical difficulties. However, interspecies differences in pancreatic structure and development are considerable. Therefore, data obtained in experiments on animals and cell cultures must be supplemented with information obtained directly from human pancreatic autopsies. In this chapter, we summarise our previous results and the literature data on human pancreatic ontogeny. Special attention has been paid to the endocrine pancreas, which undergoes morphogenetic restructuring during human development. Several forms of structural organisation of the endocrine pancreas (single endocrine cells, small clusters of endocrine cells, mantle, bipolar, and mosaic islets) gradually appear during development. It is important that this restructuring is accompanied by changes in the ratio of pancreatic endocrine cells. The mechanisms of these changes are still unclear. The difficulties in identifying progenitor cells and tracking cell differentiation are the main problems associated with this issue.

show abstract

Section: Pancreas Structure In Adultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ontogeny of the Human Pancreas

Proshchina¹,

Krivova²,

Гуревич³

et al. 2019

Comparative Endocrinology of Animals

View full text Add to dashboard Cite

show abstract

“…The latter include among others, replication of pre‐existing β‐cells, neogenesis from ductal and non‐β‐cell progenitors, transdifferentiation of fully differentiated acinar cells, transdetermination of liver progenitor cells, and the directed differentiation of stem cells/β‐cell progenitors [17–19]. β‐Cell‐immune protection strategies include a wide variety of antigen‐specific or broad‐based immunosuppressive, immunomodulatory, and tolerance‐inducing therapies and immunoisolation techniques such as cell encapsulation using bioscaffolds supplemented with angiogenic factors and anti‐inflammatory drugs [9, 17]. However, as we have discovered over the last decade, no single intervention standing alone has succeeded in curing this multifactorial, multistage disease.…”

Section: Therapeutic Interventions To Treat T1dmentioning

confidence: 99%

“…They also release immunosuppressive, anti‐inflammatory, and tolerogenic cytokines/chemokines, express a number of proangiogenic growth factors, and form cell‐to‐cell inhibitory interactions. These properties potentially enable BM‐MSCs to abrogate immune injury, enhance β‐cell repair/regeneration, promote longitudinal islet graft survival, and counteract autoimmunity [17, 77–79]. For example, administration of in vitro expanded syngeneic BM‐MSCs into STZ‐induced diabetic rats was able to induce sustained normoglycemia, alter T‐cell cytokine pattern toward IL‐10/IL‐13 production, and preserve Tregs in the periphery, establishing a tissue microenvironment that supported β‐cell activation/survival in the pancreas [80].…”

Section: Stem Cell‐based Strategies For β‐Cell Regeneration and Immunmentioning

confidence: 99%

Stem Cell Therapy to Cure Type 1 Diabetes: From Hype to Hope

Chhabra

Brayman

2013

Stem Cells Translational Medicine

Self Cite

141

View full text Add to dashboard Cite

Type 1 diabetes mellitus (T1D) is a chronic, multifactorial autoimmune disease that involves the progressive destruction of pancreatic β-cells, ultimately resulting in the loss of insulin production and secretion. The goal of clinical intervention is to prevent or arrest the onset and progression of autoimmunity, reverse β-cell destruction, and restore glycometabolic and immune homeostasis. Despite promising outcomes observed with islet transplantation and advancements in immunomodulatory therapies, the need for an effective cell replacement strategy for curing T1D still persists. Stem cell therapy offers a solution to the cited challenges of islet transplantation. While the regenerative potential of stem cells can be harnessed to make available a self-replenishing supply of glucose-responsive insulin-producing cells, their immunomodulatory properties may potentially be used to prevent, arrest, or reverse autoimmunity, ameliorate innate/alloimmune graft rejection, and prevent recurrence of the disease. Herein, we discuss the therapeutic potential of stem cells derived from a variety of sources for the cure of T1D, for example, embryonic stem cells, induced pluripotent stem cells, bone marrow-derived hematopoietic stem cells, and multipotent mesenchymal stromal cells derived from bone marrow, umbilical cord blood, and adipose tissue. The benefits of combinatorial approaches designed to ensure the successful clinical translation of stem cell therapeutic strategies, such as approaches combining effective stem cell strategies with islet transplantation, immunomodulatory drug regimens, and/or novel bioengineering techniques, are also discussed. To conclude, the application of stem cell therapy in the cure for T1D appears extremely promising.

show abstract

Contemporary Assessment of Stem Cell Therapies for Type 1 Diabetes Mellitus—Time for Optimism

Chhabra¹,

Brayman²

2018

Reference Module in Biomedical Sciences

View full text Add to dashboard Cite

Present Accomplishments and Future Prospects of Cell-Based Therapies for Type 1 Diabetes Mellitus

Cited by 7 publications

References 217 publications

Ontogeny of the Human Pancreas

Ontogeny of the Human Pancreas

Stem Cell Therapy to Cure Type 1 Diabetes: From Hype to Hope

Contemporary Assessment of Stem Cell Therapies for Type 1 Diabetes Mellitus—Time for Optimism

Contact Info

Product

Resources

About